SynthesisFrontiers in pharmacology2025
Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Efficacy and Safety of Integrated Traditional Chinese Medicine and Biologic Treatment in Moderate to Severe Atopic Dermatitis: Protocol for a Prospective Observational Real-World Study.JMIR research protocols · 2026Article
- Immunochemical Markers and Quality of Life in Severe Atopic Dermatitis: A Real-World Analysis.Journal of Korean medical science · 2026Article
- The inhibition of pathological IgE in allergic diseases by natural compounds.Natural products and bioprospecting · 2026Review
- Adjunctive Use of VGH4 for Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Trial.Life (Basel, Switzerland) · 2026Article
- Review
- Real-world efficacy and safety of dupilumab in the treatment of head and neck atopic dermatitis: a retrospective cohort study.Frontiers in medicine · 2025Article
- Acute Mood Episodes in Patients of Atopic Dermatitis Treated with Dupilumab: Insights from two Cases.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the impact of dupilumab treatment on the quality of life, psychological factors and clinical symptoms, in patients with moderate-to-severe atopic dermatitis. Methods: A comprehensive search was conducted in PubMed, Web of Science, Embase, and Cochrane Library. Data coverage extends until April 2024. The study exclusively encompassed randomized controlled trials. The primary outcome was the quality of life of patients, with subgroup analyses conducted. Revman 5.4 and Stata 15.1 software were used for the analyses. Results: This study included 17 studies with a total of 6,665 participants. To evaluate quality of life, six instruments were used: the Dermatology Life Quality Index (DLQI), the Quality of Life Index for Atopic Dermatitis (QoLIAD), the Children's Dermatology Life Quality Index (CDLQI), the Infant's Dermatitis Quality of Life Index (IDQoL), the Dermatitis Family Impact (DFI), and the EuroQol-5 Dimension (EQ-5D). The QoLIAD is specifically designed for atopic dermatitis. The results demonstrated that dupilumab significantly improved DLQI/QoLIAD scores in adult patients (SMD = -0.64, 95% CI [-0.84, -0.45], p < 0.00001), the CDLQI/IDQoL scores in children/adolescents (SMD = -0.73, 95% CI [-0.84, -0.63], p < 0.00001), family quality of life measured by DFI (SMD = -0.97, 95% CI [-1.20, -0.75], p < 0.00001), and EQ-5D scores (SMD = 0.64, 95% CI [0.46, 0.82], p < 0.00001). The study also reported significant improvements in sleep-related metrics, total score on the Hospital Anxiety and Depression Scale (HADS), HADS anxiety scale, and HADS depression score. Additional improvements were observed in the Patient-Oriented Eczema Measure (POEM), pruritus Numeric Rating Scale (NRS), Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), percent Body Surface Area (BSA), Global Individual Sign Score (GISS), and Investigator's Global Assessment (IGA) response. Conclusion: Our study demonstrates that dupilumab significantly enhances patients' quality of life and alleviates symptoms. This meta-analysis utilizes various assessment tools to evaluate quality of life, synthesizing data from recent clinical trials. It builds on prior research to provide a comprehensive analysis of dupilumab's effects and overall efficacy. The aim of this study is to offer evidence-based insights to improve the clinical application of dupilumab. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.